In this scenario, the mechanisms that bring to the loss of HIF1-α ubiquitination, and to its consequent accumulation, are yet to be fully investigated, but promoting the process may lead to the HIF transcription factor downregulation and possibly to new therapeutic approaches for osteosarcoma. This evidence concerns the gene HIF1A and osteosarcoma.